IAG
NTLA icon

Innovative Advisory Group’s Intellia Therapeutics NTLA Stock Holding History

Innovative Advisory Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5
Closed -$45 – 158
2025
Q4 		$45 Hold
5
– – ﹤0.01% 246
2025
Q3 		$86 Hold
5
– – ﹤0.01% 245
2025
Q2 		$47 Hold
5
– – ﹤0.01% 249
2025
Q1 		$36 Hold
5
– – ﹤0.01% 236
2024
Q4 		$58 Buy
+5
New +$78 ﹤0.01% 227

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Innovative Advisory Group's NTLA Position: Q1 2026 in Review

Innovative Advisory Group sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 5 shares — an estimated $45 sold.

Innovative Advisory Group first reported a position in NTLA in Q4 2024 and held it in 5 quarters. The position peaked at $86 in Q3 2025. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Innovative Advisory Group reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Innovative Advisory Group sold 5 Intellia Therapeutics shares in Q1 2026, an estimated $45.
  • Innovative Advisory Group first reported a position in Intellia Therapeutics in Q4 2024 and held it in 5 quarters.
  • Innovative Advisory Group's Intellia Therapeutics position peaked at $86 in Q3 2025.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Innovative Advisory Group's 13F filing for Q1 2026, filed 22 Sep 2026.